N'-(2-methoxyethyl)-N'-methylethane-1,2-diamine | 14165-17-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N'-(2-methoxyethyl)-N'-methylethane-1,2-diamine
• 英文别名: N1-(2-methoxyethyl)-N1-methylethane-1,2-diamine；N1-(2-methoxyethyl)-N1-methyl-1,2-ethanediamine；N-(2-Methoxy-aethyl)-N-methyl-aethylendiamin；(2-Aminoethyl)(2-methoxyethyl)methylamine
• CAS: 14165-17-4
• 化学式: C₆H₁₆N₂O
• mdl: MFCD12167393
• 分子量: 132.206
• InChiKey: VZROIUNAVVHTDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N'-(2-methoxyethyl)-N'-methylethane-1,2-diamine 、 2-甲基-2-疏基硫酸脲 生成 <2-(2-Methoxy-N-methyl-aethylamino)-aethyl>-guanidin
  参考文献：
  名称：

  Pasini; Coda; Colò, Farmaco, Edizione Scientifica, 1965, vol. 20, # 10, p. 673 - 685

  摘要：

  DOI：
• 作为产物：
  描述：

  [(2-methoxyethyl)(methyl)amino]acetonitrile 在 镍 氢气 、 乙醇 作用下， 以 乙醇 为溶剂， 35.0 ℃ 、55.15 MPa 条件下， 反应 5.0h， 以to give crude diamine 268 (Pasini, C.; et al., Farmaco, Edizione Scientifica 1965, 20, 673-685) (2.45 g, 79%) as a colourless oil, which的产率得到N'-(2-methoxyethyl)-N'-methylethane-1,2-diamine
  参考文献：
  名称：

  Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments

  摘要：

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，涉及它们的制备，以及它们作为缺氧选择性药物和放射增敏剂用于癌症治疗，无论是单独使用还是与放射治疗和/或其他抗癌药物联合使用。

  公开号：

  US07989451B2

文献信息

• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。
• [EN] (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL) UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT<br/>[FR] DÉRIVÉS DE (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TÉTRAHYDRONAPHTALÉN-1-YL)URÉIDO EN TANT QU'INHIBITEURS DE P38 MAPK ANTI-INFLAMMATOIRES POUR TRAITER DES MALADIES DU TRACTUS RESPIRATOIRE
  申请人：CHIESI FARM SPA

  公开号：WO2018224423A1

  公开（公告）日：2018-12-13

  This invention relates to (4-(([l,2,4]triazolo[4,3-a]pyridine-6-yl) oxy)-1,2,3,4-tetrahydronaphthalen-1-yl)ureido derivatives that are p38 MAPK (mitogen activated protein kinase) inhibitors as antiinflammatory agents for treating diseases of the respiratory tract.

  本发明涉及(4-(([1,2,4]三唑[4,3-a]吡啶-6-基)氧基)-1,2,3,4-四氢萘-1-基)脲衍生物，该衍生物作为抗炎剂用于治疗呼吸道的疾病，是p38 MAPK（丝裂原活化蛋白激酶）的抑制剂。
• [EN] (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS<br/>[FR] DERIVES D'AMINOETHYLAMIDE D'ACIDE (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIQUE UTILISES COMME MODULATEURS DU RECEPTEUR DE L'IL-8 POUR TRAITER L'ATHEROSCLEROSE ET LA POLYARTHRITE RHUMATOIDE
  申请人：PHARMACOPEIA DRUG DISCOVERY

  公开号：WO2004069829A1

  公开（公告）日：2004-08-19

  The invention relates to compounds of the formula: (I); wherein R1 is a basic moiety having the structure -NH(CH2)2NR5R6, (Formula II) or (Formula II); wherein R5, R6 and R7 are independently selected from H, (1-6C)alkyl, (2-6C)alkenyl; (3-8C)cycloalkyl, and (1-6C)alkyl substituted with furanyl, (1-6C)alkoxy, (3-8C)cycloalkyl, trifluoromethyl or amido; or R5 and R6 together with N to which they are attached are a (4-8) membered heterocycle, which heterocycle may be substituted with (1-6C)alkoxy, trifluoromethyl or amido and which heterocycle may be fused with another (5-6) membered heterocycle; n is 1, 2 or 3; and the ring structure A represents a (4-6) membered heterocycle; R2 is (1-6C)alkyl, optionally substituted with (1-6C)alkoxy; R3 is aryl, heterocyclyl, -X-(CH2)maryl or -X-(CH2)m-heterocyclyl, wherein X is O, S or NR8, R8 being H or (1-6C)alkyl, and m is 0, 1, 2 or 3; and R4 is H, (1-8C)akyl, (1-8C)alkoxy or (2-8C)alkenyl, the alkyl moiety of each optionally being substituted with hydroxy, halogen, cyano, nitro, oxo, amino, alkylamino, dialkylamino, amido, alkylamido, carboxy, (1-8C)alkoxy, (1-8C)alkylthio, perfluoro (1-4C)alkyl, (3-8C)cycloalky, aryl, aryloxy, heterocyclyl or-0-heterocyclyl; or a pharmaceutically acceptable salt thereof. The compounds of the invention are Il-8 receptor modulators, in particular inhibitors thereof, and can be used for treating or preventing Il-8 receptor mediated disorders, such as atherosclerosis, inflammation, rheumatoid arthritis and related disorders.

  该发明涉及以下式的化合物：（I）；其中R1是具有结构-NH(CH2)2NR5R6的碱性基团，（式II）或（式II）；其中R5、R6和R7分别选自H、（1-6C）烷基、（2-6C）烯基；（3-8C）环烷基，以及用呋喃基、（1-6C）烷氧基、（3-8C）环烷基、三氟甲基或酰胺取代的（1-6C）烷基；或者R5和R6与它们连接的N一起是（4-8）成员杂环，该杂环可以用（1-6C）烷氧基、三氟甲基或酰胺取代，并且该杂环可以与另一个（5-6）成员杂环融合；n为1、2或3；环结构A代表（4-6）成员杂环；R2是（1-6C）烷基，可选地取代（1-6C）烷氧基；R3是芳基、杂环基、-X-(CH2)芳基或-X-(CH2)m-杂环基，其中X为O、S或NR8，R8为H或（1-6C）烷基，m为0、1、2或3；R4为H、（1-8C）烷基、（1-8C）烷氧基或（2-8C）烯基，每个烷基基团可选地取代羟基、卤素、氰基、硝基、氧代、氨基、烷基氨基、二烷基氨基、酰胺、烷基酰胺、羧基、（1-8C）烷氧基、（1-8C）烷基硫氧基、全氟（1-4C）烷基、（3-8C）环烷基、芳基、芳氧基、杂环基或-0-杂环基；或其药学上可接受的盐。该发明的化合物是Il-8受体调节剂，特别是其抑制剂，并可用于治疗或预防Il-8受体介导的疾病，如动脉粥样硬化、炎症、类风湿关节炎及相关疾病。
• Sulfonamide compound
  申请人：Matsubara Koki

  公开号：US20090048223A1

  公开（公告）日：2009-02-19

  A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R 3 )(R 4 )— (R 3 and R 4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G 4 represents hydroxyl group (Y is a single group), or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.

  由以下化学式表示的化合物：[A代表含氮饱和环；m表示0到2的整数；n表示1到4的整数；G1代表氢原子、氯原子、羟基、烷氧基或氨基；G2代表卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；G3代表氢原子、卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；Y代表单键，或-C(R3)(R4)-（R3和R4代表氢原子、烷基或烷烯基，它们结合在一起形成饱和碳氢环基）；G4代表羟基（Y是单个基），或-N(R1)(R2)（R1和R2代表氢原子、烷基、芳基、烯基、炔基、饱和杂环基、烷基磺酰基、酰基或胺基）；G5是A的环构成碳原子上的取代基，代表氢原子、氟原子或烷基]或其盐、或作为前药的衍生物，其强力抑制Rho激酶。